https://www.skintherapyletter.com Written by Dermatologists for Dermatologists Tue, 29 Jul 2025 18:40:43 +0000 en-US hourly 1 https://wordpress.org/?v=6.8.1 https://www.skintherapyletter.com/download/pdf-drug-update-july-august-2025/ Tue, 29 Jul 2025 18:26:16 +0000 https://www.skintherapyletter.com/?post_type=product&p=16049 PDF Download: Update on Dupilumab SC injection (Dupixent®), Garadacimab-gxii for SC injection (Andembry®), Roflumilast foam, 0.3% (Zoryve®), Ustekinumab-hmny for SC injection (Starjemza®), Ustekinumab biosimilar SC/IV use (Otulfi®) and Prademagene zamikeracel genemodified cellular sheets (Zevaskyn™). Read online: Update on Drugs & Devices: July-August 2025]]> PDF Download: Update on Dupilumab SC injection (Dupixent®), Garadacimab-gxii for SC injection (Andembry®), Roflumilast foam, 0.3% (Zoryve®), Ustekinumab-hmny for SC injection (Starjemza®), Ustekinumab biosimilar SC/IV use (Otulfi®) and Prademagene zamikeracel genemodified cellular sheets (Zevaskyn™). Read online: Update on Drugs & Devices: July-August 2025]]> https://www.skintherapyletter.com/download/pdf-nanodermatology/ Tue, 29 Jul 2025 18:21:19 +0000 https://www.skintherapyletter.com/?post_type=product&p=16048 PDF Download: Nanodermatology uses nanoparticles (1-1000 nanometers) to enhance transdermal drug delivery for treating psoriasis, vitiligo, acne, and atopic dermatitis. Learn about nanocarriers, liposomes, and how nanotechnology improves topical medication penetration while reducing side effects. Read online: Nanodermatology]]> PDF Download: Nanodermatology uses nanoparticles (1-1000 nanometers) to enhance transdermal drug delivery for treating psoriasis, vitiligo, acne, and atopic dermatitis. Learn about nanocarriers, liposomes, and how nanotechnology improves topical medication penetration while reducing side effects. Read online: Nanodermatology]]> https://www.skintherapyletter.com/download/pdf-lebrikizumab-moderate-to-severe-atopic-dermatitis/ Tue, 29 Jul 2025 18:15:29 +0000 https://www.skintherapyletter.com/?post_type=product&p=16047 PDF Download: Lebrikizumab is a new IL-13 targeting monoclonal antibody approved for moderate-to-severe atopic dermatitis in patients 12+ years. Learn about clinical trial efficacy, safety data, dosing, and how it compares to other AD biologics like dupilumab and tralokinumab. Read online: Lebrikizumab for Moderate-to-Severe Atopic Dermatitis ]]> PDF Download: Lebrikizumab is a new IL-13 targeting monoclonal antibody approved for moderate-to-severe atopic dermatitis in patients 12+ years. Learn about clinical trial efficacy, safety data, dosing, and how it compares to other AD biologics like dupilumab and tralokinumab. Read online: Lebrikizumab for Moderate-to-Severe Atopic Dermatitis ]]> https://www.skintherapyletter.com/download/pdf-jul-aug-2025/ Tue, 29 Jul 2025 18:03:52 +0000 https://www.skintherapyletter.com/?post_type=product&p=16046 PDF Download:

Articles in this Issue:

1. Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
2. Nanodermatology
3. Update on Drugs & Devices: July-August 2025

]]> PDF Download:

Articles in this Issue:

1. Lebrikizumab for Moderate-to-Severe Atopic Dermatitis
2. Nanodermatology
3. Update on Drugs & Devices: July-August 2025

]]> https://www.skintherapyletter.com/download/pdf-drug-update-may-june-2025/ Tue, 03 Jun 2025 20:37:49 +0000 https://www.skintherapyletter.com/?post_type=product&p=15966 PDF Download: Update on Tapinarof cream 1% (Nduvra™), Omalizumab-igec for SC injection (Omlyclo®) and Retifanlimab for IV infusion (Zynyz®). Read online: Update on Drugs & Devices: May-June 2025]]> PDF Download: Update on Tapinarof cream 1% (Nduvra™), Omalizumab-igec for SC injection (Omlyclo®) and Retifanlimab for IV infusion (Zynyz®). Read online: Update on Drugs & Devices: May-June 2025]]> https://www.skintherapyletter.com/download/pdf-triple-combination-therapy-idp-126-acne/ Tue, 03 Jun 2025 20:33:39 +0000 https://www.skintherapyletter.com/?post_type=product&p=15965 PDF Download: IDP-126 is a novel fixed-dose topical gel combining clindamycin, benzoyl peroxide, and adapalene for moderate to severe acne. Approved by the FDA and Health Canada, it showed superior efficacy over dual therapies in phase 2 and 3 trials, with strong safety and tolerability outcomes. Read online: A Novel Fixed Dose Triple Combination Therapy (IDP-126) for Moderate to Severe Acne]]> PDF Download: IDP-126 is a novel fixed-dose topical gel combining clindamycin, benzoyl peroxide, and adapalene for moderate to severe acne. Approved by the FDA and Health Canada, it showed superior efficacy over dual therapies in phase 2 and 3 trials, with strong safety and tolerability outcomes. Read online: A Novel Fixed Dose Triple Combination Therapy (IDP-126) for Moderate to Severe Acne]]> https://www.skintherapyletter.com/download/pdf-nemolizumab-prurigo-nodularis-atopic-dermatitis/ Tue, 03 Jun 2025 20:28:19 +0000 https://www.skintherapyletter.com/?post_type=product&p=15964 PDF Download: Nemolizumab, an IL-31 receptor antagonist, has demonstrated high efficacy and a favourable safety profile in phase 3 trials for prurigo nodularis and atopic dermatitis. Patients showed significant reductions in itch, improved skin lesions, and better quality of life over extended treatment periods. Read online: Use of Nemolizumab in the Treatment of Prurigo Nodularis and Atopic Dermatitis]]> PDF Download: Nemolizumab, an IL-31 receptor antagonist, has demonstrated high efficacy and a favourable safety profile in phase 3 trials for prurigo nodularis and atopic dermatitis. Patients showed significant reductions in itch, improved skin lesions, and better quality of life over extended treatment periods. Read online: Use of Nemolizumab in the Treatment of Prurigo Nodularis and Atopic Dermatitis]]> https://www.skintherapyletter.com/download/pdf-may-jun-2025/ Tue, 03 Jun 2025 20:14:04 +0000 https://www.skintherapyletter.com/?post_type=product&p=15962 PDF Download:

Articles in this Issue:

1. Use of Nemolizumab in the Treatment of Prurigo Nodularis and Atopic Dermatitis
2. A Novel Fixed Dose Triple Combination Therapy (IDP-126) for Moderate to Severe Acne
3. Update on Drugs & Devices: May-June 2025

]]> PDF Download:

Articles in this Issue:

1. Use of Nemolizumab in the Treatment of Prurigo Nodularis and Atopic Dermatitis
2. A Novel Fixed Dose Triple Combination Therapy (IDP-126) for Moderate to Severe Acne
3. Update on Drugs & Devices: May-June 2025

]]> https://www.skintherapyletter.com/download/pdf-drug-update-march-april-2025/ Thu, 13 Mar 2025 21:18:01 +0000 https://www.skintherapyletter.com/?post_type=product&p=15842 PDF Download: Update on Mirdametinib 1 mg tablets for oral suspension & 1 mg/2 mg capsules (Gomekli™), Ustekinumab-stba SC/IV injection (Steqeyma®) and Nivolumab + hyaluronidase-nvhy for SC injection (Opdivo Qvantig™). Read online: Update on Drugs & Devices: March-April 2025]]> PDF Download: Update on Mirdametinib 1 mg tablets for oral suspension & 1 mg/2 mg capsules (Gomekli™), Ustekinumab-stba SC/IV injection (Steqeyma®) and Nivolumab + hyaluronidase-nvhy for SC injection (Opdivo Qvantig™). Read online: Update on Drugs & Devices: March-April 2025]]> https://www.skintherapyletter.com/download/pdf-psoriatic-arthritis-guselkumabnt/ Wed, 12 Mar 2025 15:15:13 +0000 https://www.skintherapyletter.com/?post_type=product&p=15841 PDF Download: Discover the role of IL-23 inhibition in psoriatic arthritis with a detailed review of guselkumab’s efficacy, safety, and practical use. This article summarizes key clinical trial findings, patient outcomes, and compares guselkumab to other biologic treatments, emphasizing its value as an alternative therapeutic option. Read online: Targeting IL-23 in Psoriatic Arthritis: A Review of Guselkumab’s Efficacy and Utilization]]> PDF Download: Discover the role of IL-23 inhibition in psoriatic arthritis with a detailed review of guselkumab’s efficacy, safety, and practical use. This article summarizes key clinical trial findings, patient outcomes, and compares guselkumab to other biologic treatments, emphasizing its value as an alternative therapeutic option. Read online: Targeting IL-23 in Psoriatic Arthritis: A Review of Guselkumab’s Efficacy and Utilization]]>